Fig. 4
a Change from baseline in FEV1 over time. Data reported as LS mean ± SE; p < 0.05 abediterol (all doses) vs placebo, all time points; p < 0.05 abediterol 2.5–10 μg vs indacaterol, all time points from 0.5 h post-dose. b Placebo-subtracted change from baseline in FEV1 AUC0–24. c Placebo-subtracted change from baseline in peak FEV1 (per-protocol population). a p < 0.05 abediterol (all doses) vs placebo, all time points; p < 0.05 abediterol 2.5–10 μg vs indacaterol, all time points from 0.5 h post-dose. Data reported as LS means with 95 % CIs (ANCOVA). b ****p < 0.0001 vs placebo; ††††p < 0.0001 vs indacaterol. Data reported as LS mean difference from placebo (ANCOVA) ± SE. c ****p < 0.0001 vs placebo, ††††p < 0.0001 vs indacaterol. Data reported as LS mean difference from placebo (ANCOVA) ± SE. ANCOVA, analysis of covariance; AUC0-24/24, area under the curve over the 24 h period immediately after morning IMP administration; CI, confidence interval; FEV1, forced expiratory volume in 1 s; IMP, investigational medicinal product; LS, least squares; SE, standard error